US Patent 7173039 Protein kinase inhibitors
Patent 7173039 was granted and assigned to Theravance on February, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 31 Aug, 2023
Golden AI
Edits made to:
Article (+370 characters)
Article
Patent abstract
Disclosed are compounds which inhibit or modulate the activity of protein kinases and pharmaceutical compositions containing such compounds. The disclosed compound contain two or more ligand moieties covalently linked together by one or more linking groups. Such compounds are useful for treating diseases or medical disorders mediated by protein kinases.
Edits on 21 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07173039 Protein kinase inhibitors US Patent 7173039 Protein kinase inhibitors
Infobox
Patent Number
0717303900
Patent Number
717303900
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
071730390
Date of Patent
February 6, 2007
0Patent Application Number
111787360
Date Filed
July 11, 2005
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
071730390
Date of Patent
February 6, 2007
0Patent Application Number
111787360
Date Filed
July 11, 2005
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 20 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07173039 Protein kinase inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07173039
Date of patent
February 6, 2007
Patent application number
11178736
Date Filed
July 11, 2005
Patent primary examiner
Find more entities like US Patent 7173039 Protein kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.